Spectrum Pharmaceuticals, Inc. - Common Stock (NQ:SPPI)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 31, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Spectrum Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stocks That Hit 52-Week Lows On Monday ↗

December 19, 2022

On Monday, 297 companies reached new 52-week lows.

Via Benzinga

ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPPI

December 17, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

After FDA Rejection, Spectrum Shelves Development On Poziotinib ↗

November 25, 2022

Via Benzinga

Expert Ratings for Spectrum Pharmaceuticals ↗

November 16, 2022

Via Benzinga

SPPI EQUITY NOTICE: Rosen Law Firm Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI

December 12, 2022

From The Rosen Law Firm, P.A.

Via Business Wire

Spectrum Pharmaceuticals, Inc. (SPPI) Shareholder Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Spectrum Pharmaceuticals, Inc.

December 12, 2022

From Robbins LLP

Via Business Wire

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

December 07, 2022

From The Schall Law Firm

Via Business Wire

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Spectrum Pharmaceuticals, Inc. (SPPI)

December 06, 2022

From Robbins LLP

Via Business Wire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Class Action on Behalf of Investors in Spectrum Pharmaceuticals, Inc. and Advises Shareholders with Losses of $100,000 to Contact the Firm

December 06, 2022

From The Schall Law Firm

Via Business Wire

Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors

December 06, 2022

From Spectrum Pharmaceuticals, Inc.

Via Business Wire

Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff

December 05, 2022

From Spectrum Pharmaceuticals

Via Business Wire

Bragar Eagel & Squire, P.C. Is Investigating Spectrum, F45 Training, PROG, and Fox and Encourages Investors to Contact the Firm

December 02, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

Marathon Oil To Rally Around 65%? Plus This Analyst Cuts PT On Twilio By 55% ↗

November 28, 2022

Raymond James raised the price target on Marathon Oil Corporation (NYSE: MRO) from $37 to $48. Raymond James analyst John Freeman maintained a Strong Buy rating on the stock. Marathon Oil shares fell...

Via Benzinga

Bragar Eagel & Squire, P.C. Is Investigating GrafTech, Cantaloupe, Spectrum, and F45 Training and Encourages Investors to Contact the Firm

November 27, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 25, 2022

Via Benzinga

Why Lufax Holding Shares Are Trading Lower By Over 11%; Here Are 21 Stocks Moving Premarket ↗

November 25, 2022

Gainers VEON Ltd. (NASDAQ: VEON) shares rose 31.1% to $0.6095 in pre-market trading after the company agreed to sell its Russian business, Vimpelcom for 130 billion roubles ($2.2 billion).

Via Benzinga

Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection

November 25, 2022

From Spectrum Pharmaceuticals, Inc.

Via Business Wire

Bragar Eagel & Squire, P.C. Is Investigating GrafTech, Cantaloupe, Spectrum, and F45 Training and Encourages Investors to Contact the Firm

November 16, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022 ↗

November 16, 2022

Upgrades

Via Benzinga

Spectrum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 10, 2022

From Spectrum Pharmaceuticals, Inc.

Via Business Wire

Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, Spectrum, and F45 Training and Encourages Investors to Contact the Firm

November 06, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Earnings Scheduled For November 10, 2022 ↗

November 10, 2022

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter.

Via Benzinga

Spectrum Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update

November 03, 2022

From Spectrum Pharmaceuticals, Inc.

Via Business Wire

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

EQUITY ALERT: Rosen Law Firm Encourages Spectrum Pharmaceuticals, Inc. Investors to Inquire About Class Action Investigation – SPPI

October 28, 2022

From Rosen Law Firm

Via Business Wire

Bragar Eagel & Squire, P.C. Is Investigating Spectrum, F45 Training, PROG, and UiPath and Encourages Investors to Contact the Firm

October 21, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™ (eflapegrastim-xnst) Injection

October 21, 2022

From Spectrum Pharmaceuticals, Inc.

Via Business Wire

Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, F45, and PROG and Encourages Investors to Contact the Firm

October 16, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, and F45 and Encourages Investors to Contact the Firm

October 11, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.